For example, SLC7A11 provides resistance to BRAF and MEK inhibitors in BRAFV600E mutant melanoma, geldanamycin resistance in lung cancer, cisplatin resistance in gastric cancer, temozolomide resistance in glioma and gemcitabine resistance in pancreatic cancer (84–89). Here, SLC7A11 is linked to glioma.